Drug Prices
AHA urges HHS to stop drug companies’ refusal to provide required 340B discounts
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation provides an incomplete picture of U.S. spending on health care while downplaying the “immense role” that drug costs play, writes Aaron Wesolowski, AHA’s vice president of policy research, analytics and…
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries,” does not provide a full picture on health care spending in the U.S. while also downplaying the immense role that drug costs play in…
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation’s costliest drugs. As part of the hearing, Committee Chairwoman Carolyn Maloney, D-N.Y., released additional staff reports describing repeated actions by drug…
The House Committee on Oversight and Reform launched a two-day hearing to examine pricing practices for some of the nation’s costliest drugs.
The Food and Drug Administration released a final rule allowing states, territories and Indian tribes to establish programs to import certain FDA-approved prescription drug and biological products from Canada.
President Trump issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human Services to test a “most-favored-nation” pricing model for Part B, and some Part D, drugs.
Summary of President Trump’s executive order to address drug pricing via “most-favored-nation” pricing model.
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana DeGette, D-Colo., and David McKinley, R-W.Va., along with Reps. Peter Welch, D-Vt., Greg Gianforte, R-Mont., Dusty Johnson, R-S.D., and…
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.